Blends & Stacks

Pre-Formulated Peptide Blends: Rationale and Evidence

Peptide blends co-formulate two or more compounds in a single vial at defined ratios. The rationale for pre-blending is not commercial convenience alone — it rests on documented mechanistic complementarity between the components. Each combination discussed here has a published research basis for the pairing.

Recovery Stack: BPC-157 + TB-500

The BPC-157/TB-500 combination is the most extensively studied peptide pairing in recovery-focused research. Sometimes referred to informally as the Wolverine Stack, the rationale is precise.

Why These Two Together

BPC-157 and TB-500 operate through non-overlapping primary mechanisms:

• BPC-157: VEGFR2-driven angiogenesis, FAK-Paxillin cell migration, NO-system mucosal repair — primarily local in distribution
• TB-500: G-actin sequestering driving F-actin polymerisation and cell motility — systemically distributed via circulation

Their half-lives differ substantially: BPC-157 approximately 4 hours; TB-500 approximately 10 days. A standard protocol thus doses BPC-157 daily or twice daily while TB-500 is dosed 1–2× per week. Pre-blending in a single vial with a 1:1 ratio covers the acute BPC-157 signalling event while co-delivering the weekly TB-500 dose — simplifying reconstitution and administration without altering the individual compound pharmacology.

Typical Protocol

Loading phase: 5 mg BPC-157 + 5 mg TB-500 twice weekly for 4 weeks. Maintenance: 2.5 mg each weekly thereafter. Timing is flexible — no known food or fasting interaction.

GH Secretagogue Stack: Ipamorelin + CJC-1295

The dual GH secretagogue blend combines GHRH-receptor stimulation (CJC-1295 No DAC) with ghrelin-receptor stimulation (Ipamorelin). The synergy rationale is well-established: the two receptors amplify GH pulse output additively, producing larger secretory events than either compound alone at equivalent doses.

Blend Ratio

A 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin formulation provides balanced dosing for the standard 100–200 mcg each per pulse. Pre-blending ensures consistent ratio delivery across the protocol.

Protocol Timing

Dosed pre-sleep is the primary research timing — aligning with the natural nocturnal GH pulse. Additional dosing pre-workout or in a fasted morning state is common. Avoiding carbohydrate intake within 90 minutes of administration minimises somatostatin suppression of the GH pulse.

Metabolic Blends: Cagri-Sema and Cagri-Reta

Cagrilintide + Semaglutide (CagriSema)

Cagrilintide is a long-acting amylin analogue; Semaglutide is a GLP-1R monoagonist. Amylin and GLP-1 receptor systems produce central satiety signalling through distinct hypothalamic pathways — combining them engages two non-competing mechanisms simultaneously.

The SCALE NEXT Phase 2 trial tested CagriSema vs its components in head-to-head arms. Results at 32 weeks: −15.6% body weight for CagriSema vs −8.0% for semaglutide alone and −8.1% for cagrilintide alone. Notably, GI tolerability in the combination arm was comparable to or better than semaglutide alone — supporting the mechanistic hypothesis that amylin pathway activation partially attenuates GLP-1-driven GI burden.

Cagrilintide + Retatrutide (Cagri-Reta)

Extending the amylin + GLP strategy to a triagonist backbone. Retatrutide's triple receptor coverage (GLP-1R + GIPR + GcgR) combined with amylin receptor agonism represents the leading edge of multi-target metabolic research. No direct Phase 2/3 head-to-head trial data exists for this combination as of the current evidence base. Mechanistic rationale is sound — four non-overlapping pathways — but trial validation is pending.

What to Watch for with Blends

Blend-specific considerations:

• Ratio appropriateness: Pre-formulated ratios are designed for typical research protocols. Researchers requiring asymmetric dosing (e.g., higher BPC-157 relative to TB-500) may prefer individual vials
• Stability: Peptide blends in a shared solvent must be validated for component stability at the stored concentration. Purity and stability of both components at formulation should be confirmed via COA
• Dose calculation: Each component's dose is drawn from the same volume — verify the concentration/component before administration calculations